Lactobacillli expressing llama VHH fragments neutralise Lactococcus phages. 2007

Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
Division of Clinical Immunology at the Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital in Huddinge, Stockholm, Sweden. A.H.Hultberg@uu.nl

BACKGROUND Bacteriophages infecting lactic acid bacteria (LAB) are widely acknowledged as the main cause of milk fermentation failures. In this study, we describe the surface-expression as well as the secretion of two functional llama heavy-chain antibody fragments, one binding to the major capsid protein (MCP) and the other to the receptor-binding proteins (RBP) of the lactococcal bacteriophage p2, by lactobacilli in order to neutralise lactococcal phages. RESULTS The antibody fragment VHH5 that is directed against the RBP, was fused to a c-myc tag and expressed in a secreted form by a Lactobacillus strain. The fragment VHH2 that is binding to the MCP, was fused to an E-tag and anchored on the surface of the lactobacilli. Surface expression of VHH2 was confirmed by flow cytometry using an anti-E-tag antibody. Efficient binding of both the VHH2 and the secreted VHH5 fragment to the phage antigens was shown in ELISA. Scanning electron microscopy showed that lactobacilli expressing VHH2 anchored at their surface were able to bind lactococcal phages. A neutralisation assay also confirmed that the secreted VHH5 and the anchored VHH2 fragments prevented the adsorption of lactococcal phages to their host cells. CONCLUSIONS Lactobacilli were able to express functional VHH fragments in both a secreted and a cell surface form and reduced phage infection of lactococcal cells. Lactobacilli expressing llama heavy-chain antibody fragments represent a novel way to limit phage infection.

UI MeSH Term Description Entries
D007128 Immunoglobulin Fragments Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques. Antibody Fragment,Antibody Fragments,Ig Fragment,Ig Fragments,Immunoglobulin Fragment,Fragment, Antibody,Fragment, Ig,Fragment, Immunoglobulin,Fragments, Antibody,Fragments, Ig,Fragments, Immunoglobulin
D007778 Lactobacillus A genus of gram-positive, microaerophilic, rod-shaped bacteria occurring widely in nature. Its species are also part of the many normal flora of the mouth, intestinal tract, and vagina of many mammals, including humans. Lactobacillus species are homofermentative and ferment a broad spectrum of carbohydrates often host-adapted but do not ferment PENTOSES. Most members were previously assigned to the Lactobacillus delbrueckii group. Pathogenicity from this genus is rare.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002161 Camelids, New World Camelidae of the Americas. The extant species are those originating from South America and include alpacas, llamas, guanicos, and vicunas. Alpacas,Guanacos,Llamas,Lama glama,Lama glama guanicoe,Lama guanicoe,Lama pacos,Vicugna pacos,Vicugna vicugna,Vicunas,Alpaca,Camelid, New World,Guanaco,Llama,New World Camelid,New World Camelids,Vicuna
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001435 Bacteriophages Viruses whose hosts are bacterial cells. Phages,Bacteriophage,Phage
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D024861 Genetic Enhancement The use of genetic methodologies to improve functional capacities of an organism rather than to treat disease. Enhancement, Genetic,Enhancements, Genetic,Genetic Enhancements

Related Publications

Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
April 1999, Biochimica et biophysica acta,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
November 2009, Acta neuropathologica,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
October 2006, Applied microbiology and biotechnology,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
February 2000, Journal of biotechnology,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
January 2013, PLoS pathogens,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
August 2001, Journal of molecular biology,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
January 2002, Methods in molecular biology (Clifton, N.J.),
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
January 2014, PloS one,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
January 2018, F1000Research,
Anna Hultberg, and Denise M Tremblay, and Hans de Haard, and Theo Verrips, and Sylvain Moineau, and Lennart Hammarström, and Harold Marcotte
December 2006, The Journal of infectious diseases,
Copied contents to your clipboard!